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Abstract
The gene mutated in Bloom’s syndrome, BLM, is important in the repair of damaged replication forks, and it has both pro-
and anti-recombinogenic roles in homologous recombination (HR). At damaged forks, BLM interacts with RAD51
recombinase, the essential enzyme in HR that catalyzes homology-dependent strand invasion. We have previously shown
that defects in BLM modification by the small ubiquitin-related modifier (SUMO) cause increased c-H2AX foci. Because
the increased c-H2AX could result from defective repair of spontaneous DNA damage, we hypothesized that SUMO
modification regulates BLM’s function in HR repair at damaged forks. To test this hypothesis, we treated cells that stably
expressed a normal BLM (BLM+) or a SUMO-mutant BLM (SM-BLM) with hydroxyurea (HU) and examined the effects of
stalled replication forks on RAD51 and its DNA repair functions. HU treatment generated excess c-H2AX in SM-BLM
compared to BLM+ cells, consistent with a defect in replication-fork repair. SM-BLM cells accumulated increased numbers of
DNA breaks and were hypersensitive to DNA damage. Importantly, HU treatment failed to induce sister-chromatid
exchanges in SM-BLM cells compared to BLM+ cells, indicating a specific defect in HR repair and suggesting that RAD51
function could be compromised. Consistent with this hypothesis, RAD51 localization to HU-induced repair foci was impaired
in SM-BLM cells. These data suggested that RAD51 might interact noncovalently with SUMO. We found that in vitro RAD51
interacts noncovalently with SUMO and that it interacts more efficiently with SUMO-modified BLM compared to unmodified
BLM. These data suggest that SUMOylation controls the switch between BLM’s pro- and anti-recombinogenic roles in HR. In
the absence of BLM SUMOylation, BLM perturbs RAD51 localization at damaged replication forks and inhibits fork repair by
HR. Conversely, BLM SUMOylation relieves its inhibitory effects on HR, and it promotes RAD51 function.
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Introduction
Homologous recombination (HR) is a high-fidelity DNA repair
mechanism that functions to rejoin double-strand breaks (DSBs)
and restart broken replication forks. A major outcome of the repair
of replication fork damage by HR is the generation of sister-
chromatid exchanges (SCEs), which result from resolution of
Holliday junctions during HR repair [1,2]. Predictably, a large
number of agents that cause DNA damage increase the
frequencies of SCEs [3–5]. Bloom’s syndrome (BS) is the only
clinical entity in which increased levels of SCE are a prominent
cellular feature [6]. It is an autosomal recessive disorder, which is
characterized by proportional dwarfism, photosensitivity, immu-
nodeficiency, hypogonadism, and predisposition to a wide range of
different types of cancer [7]. BS is caused by biallelic null
mutations of the BLM gene [8]. The BLM gene encodes a DNA
helicase of the RecQ family, which is an evolutionarily conserved
group of enzymes that operates at the interface of DNA
replication, HR, and DNA repair [9].
The RecQ helicases are DNA-dependent ATPases that can
translocate on single-stranded DNA (ssDNA) with 39 to 59
directionality [10]. In vitro, they preferentially unwind DNA
substrates that resemble recombination intermediates, including
G4 tetrahelical DNA, Holliday junctions, double Holliday
junctions, and D-loops. A complex consisting of BLM, topoisom-
erase IIIa, BLAP75, and BLAP18 (BLAPs are BLM-associated
proteins) can ‘‘dissolve’’ a substrate representing a double Holliday
junction—a late intermediate in HR-mediated repair of DSBs—in
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strands [11–13]. This activity could provide an explanation for the
increased SCEs in BS cells; however, recent genetic and
biochemical studies have shown that BLM also has activities in
upstream parts of the HR pathway. Because BLM is recruited to
damaged replication forks early in the repair process [14–16], it
could suppress the formation of aberrant recombination interme-
diates at the replication fork. Such a mechanism has been
proposed for Sgs1, the yeast homolog of BLM [17,18]. BLM
interacts directly with the RAD51 recombinase, which is the
enzyme that catalyzes homology-dependent strand invasion
[19,20], and in vitro it can displace RAD51 from ssDNA and
unwind the invading DNA strand of a D-loop formed by RAD51
[21,22], suggesting that BLM regulates the formation of D loops.
Finally, BLM and Sgs1 each collaborate with exonucleases that
process DSBs to generate ssDNA with a 39 tail, which is the
substrate for RAD51 [23–26]. Collectively, these data show that
BLM has both pro- and anti-recombinogenic functions in HR. A
key question that emerges from these studies is how are these
different functions of BLM in HR regulated?
Modification by the small ubiquitin-related modifier (SUMO)
has emerged as an important regulator of HR [27]. In response to
replication fork damage in the budding yeast Saccharomyces cerevisiae,
the polymerase processivity factor PCNA (proliferating cell nuclear
antigen) is SUMOylated, and PCNA SUMOylation recruits the
DNA helicase Srs2 to the fork, which functions to prevent aberrant
recombination events between sister chromatids [28–31]. Mutants
of the SUMO-specific E3 ligase gene MMS21 accumulate
RAD51-dependent cruciform structures at damaged replication
forks [32], which are aberrant structures that also accumulate in
sgs1 deletion mutants [33]. These studies indicate that SUMO
modification can play important roles in response to damaged
forks; however, the role of SUMO in regulation of HR is not fully
understood, and these mechanisms have not been studied in
mammalian cells.
We have previously shown that BLM is SUMOylated and that
failure to SUMOylate BLM results in changes in BLM’s nuclear
distribution [34]. Expression in cells of SUMO-mutant BLM,
containing lysine to arginine mutations at residues 317 and 331
that prevent SUMOylation, induces excess c-H2AX foci—a
marker for DNA damage and repair—in the absence of
exogenously induced DNA damage [34]. Despite the presence of
excess c-H2AX foci and micronuclei in cells that expressed
SUMO-mutant BLM, there was insufficient evidence to conclude
that SUMO-mutant BLM generated excess DNA damage.
Because SUMOylation is known to regulate the localization of
proteins in the nucleus [35], we hypothesized that the accumu-
lation of BLM in c-H2AX foci could result from a kinetic defect in
recruitment of BLM back to the promyelocytic leukemia (PML)
nuclear bodies (PML-NBs).
In the present study, we aimed to determine how SUMOylation
regulates BLM’s function in maintaining genomic integrity. We
hypothesized that cells that express SUMO-mutant BLM have a
DNA repair defect. Characterization of cells that expressed
SUMO-mutant BLM revealed that SUMOylation of BLM
regulates its association with RAD51 and its function in HR-
mediated repair of damaged replication forks. Our data support a
model in which SUMOylation of BLM acts as a switch to regulate
its effects on recombination.
Results
Excess c-H2AX at Damaged Replication Forks in
SUMO-Mutant BLM Cells
Because BLM functions at damaged replication forks and
c-H2AX is a marker for DNA damage, we hypothesized that
SUMO-mutant BLM is defective in repair of damaged replication
forks. To gain insight into this question, we introduced GFP-BLM
expression constructs into the BS cell line GM08505, isolated
clones that stably expressed either normal BLM (BLM+ cells) or
SUMO-mutant BLM (SM-BLM cells), and studied these clones for
responses to replication fork damage. We treated SM-BLM and
BLM+ cells with 0.5 mM hydroxyurea (HU) for 24 h, which stalls
replication forks, and quantified the production of c-H2AX by
immunofluorescence, Western blot, and flow cytometry analyses
(Figure 1). The 24-h HU treatment blocks approximately 80%
of the cells in S phase, simultaneously providing a primary
synchronization of the cells and stressing replication forks through
nucleotide deprivation.
As we reported previously, untreated SM-BLM cells exhibited
higher levels of c-H2AX foci compared to untreated BLM+ cells
(35.9 vs. 16.4, respectively; Figure 1A). Treatment of SM-BLM
and BLM+ cells with HU resulted in a larger increase in c-H2AX
foci per cell in SM-BLM compared to BLM+ cells (a gain of 56.8
vs. 42.7 foci). Particularly notable were the presence of SM-BLM
cells that stained brightly with c-H2AX (Figure 1B). HU induced
twice the numbers of c-H2AX-bright nuclei in SM-BLM cells than
in BLM+ cells (Figure 1C). Consistent with the immunofluores-
cence analysis, by Western blot and flow cytometry analyses, the
levels of c-H2AX in HU-treated SM-BLM cells were higher than
in HU-treated BLM+ cells (Figure 1D and 1E).
Because the results could have been influenced by cell-cycle
effects, we analyzed nuclear DNA content and measured BrdU
incorporation at different times after release from the HU block by
flow cytometry. After treatment with HU, in both SM-BLM and
BLM+ clones, the majority of cells were blocked in early S phase,
and they progressed to mid-S phase by 6 h after release from the
HU block (Figure S1). These data indicated that differences in
position in the cell cycle or irreversibility of the S phase block did
not explain the differences in the accumulation of c-H2AX after
HU treatment of SM-BLM and BLM+ cells.
Author Summary
Replication is the process in which cellular DNA is
duplicated. DNA damage incurred during replication is
detrimental to the cell. Homologous recombination,
in which DNA sequences are exchanged between two
similar or identical strands of DNA, plays a pivotal role in
correcting replication processes that have failed due to
DNA breakage and is tightly regulated, because deficient
or excess recombination results in genomic instability.
Previous studies have implicated the DNA-processing
enzyme BLM in the regulation of homologous recom-
bination; BLM is defective in Bloom’s syndrome, which is
characterized by excess recombination and cancer sus-
ceptibility. Here, we show that modification of BLM by the
small protein SUMO controls BLM’s function in regulating
homologous recombination at sites where DNA replication
failed. We showed that cells expressing a SUMO-deficient
mutant of BLM accumulated more DNA damage and
displayed defects in repair by homologous recombination.
An enzyme involved in homologous recombination,
RAD51, displayed a defect in localization to sites where
DNA replication failed. Our data support a model in which
SUMO modification regulates BLM’s function in homolo-
gous recombination by controlling the localization of
RAD51 to failed replication sites.
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exhibited excess phosphorylated H2AX in both untreated and
HU-treated conditions. The presence of increased levels of
spontaneous and HU-induced c-H2AX strongly suggests the
presence of excess DNA damage.
Replication Fork Damage Induces Increased DSBs in
SUMO-Mutant BLM Cells
In order to obtain direct evidence for the presence of DNA
damage, we analyzed HU-treated and untreated cells for DSBs by
pulsed-field gel electrophoresis (PFGE) (Figure 2). In the absence
of treatments, SM-BLM cells exhibited over 1.5 times more DSBs
compared to BLM+ cells (Figure 2B). This result confirmed the
presence of increased numbers of DSBs consistent with the higher
numbers of c-H2AX foci. After a 24-h treatment with HU, SM-
BLM cells again exhibited 1.5 times more DSBs compared to
BLM+ cells. Because 80% of the cells are blocked with stalled
forks, the DSBs detected in HU treatment conditions likely
originate from fork breakage. After release from the HU block,
DSBs accumulated over time, with the total number of DSBs
observed in SM-BLM cells being greater at each time point than
the total number in BLM+ cells (Figure 2B). A 24-h HU treatment
induced more DSBs in BS cells compared to no treatment, and BS
cells also accumulated more DSBs after release from the HU block
compared to either SM-BLM or BLM+ cells (Figure S2).
Consistent with the PFGE analysis, the total number of HU-
induced micronuclei was greater in SM-BLM compared to BLM+
cells (Figure 2D).
We also analyzed the numbers of DSBs in cells treated with
camptothecin (CPT), which generates replication-associated DSBs
[36,37]. Treatment with different concentrations of CPT for 3 h
generated two times more DSBs in SM-BLM compared to BLM+
Figure 1. HU treatment induces more c-H2AX in SM-BLM compared to BLM+ cells. (A) Graphical representation of the average numbers of
c-H2AX foci in HU-treated and untreated BLM+ and SM-BLM cells. BLM+ and SM-BLM cells were untreated (NT) or treated with 0.5 mM HU for 24 h
(HU) and then processed for immunofluorescence. Data presented are the average of three experiments in three BLM+ and three SM-BLM clones.
Approximately 35 cells were collected in each experiment. Error bars represent standard deviations of the combined data. p-Values were calculated
using mixed effects linear models as described in Materials and Methods. *p=0.02, NT SM-BLM versus NT BLM+;* * p=0.02, HU-treated SM-BLM versus
HU-treated BLM+. (B) Excess c-H2AX-bright cells accumulate in HU-treated SM-BLM cells. Immunofluorescence images of a representative c-H2AX-
bright cell stained with antibodies to c-H2AX (left panel) and with DAPI (right panel), showing GFP-BLM fluorescence (center panel). SM-BLM localizes
to many discrete foci in c-H2AX-bright cells. Bar indicates 10 mm. (C) Graphical representation of percentages of c-H2AX-bright cells in BLM+ and SM-
BLM cells after no treatment (NT) or treatment (HU) with 0.5 mM HU for 24 h. Error bars represent standard deviations of the combined data.
*p=0.06, NT SM-BLM versus NT BLM+;* * p,10
23, HU-treated SM-BLM versus HU-treated BLM+. (D) Western blot analysis of c-H2AX levels in HU-
treated and untreated cells. Hsc70 is a control for protein loading. (E) Flow cytometry analysis of c-H2AX-stained BLM+ and SM-BLM cells. Inset
numerical values denote median fluorescence intensities in arbitrary units.
doi:10.1371/journal.pbio.1000252.g001
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SM-BLM cells (Figure 2C). Altogether, these data were consistent
with the hypothesis that SM-BLM cells have a defect in the repair
of replication-associated DSBs.
Replication Fork Damage Induces Increased Cell Death in
SUMO-Mutant BLM Cells
Because SM-BLM cells exhibited higher levels of DSBs induced
by replication damage, we expected SM-BLM cells to be
hypersensitive to DNA damage encountered during S phase. To
test this hypothesis, we compared the levels of cell death in cells
exposed to replication damage, using a standard flow cytometry
assay (Figure 3). In the absence of HU or etoposide treatment,
BLM+ and SM-BLM cells exhibited similar levels of cell death. A
24-h treatment with HU induced a 3% increase in cell death in
BLM+ cells as compared to a 10.6% increase in SM-BLM cells
(p=0.01), demonstrating that SM-BLM cells have increased
sensitivity to HU treatment alone. Similarly, a 24-h treatment with
etoposide induced an 11.3% increase in cell death in BLM+ cells
compared to a 20.7% increase in SM-BLM cells (p=0.003),
demonstrating that SM-BLM cells are also hypersensitive to
etoposide treatment compared to BLM+ cells. After HU pretreat-
ment, etoposide induced a 13.5% increase in cell death in BLM+
cells, which was similar to the level of cell death observed without
HU pretreatment (11.3%) (p=0.84), whereas after HU pretreat-
ment, etoposide induced a 43.1% increase in cell death in SM-BLM
cells, which was 2-fold greater compared to the level observed
without HU pretreatment (20.7%) (p,0.001). As expected, BS cells
that lack BLM protein are also hypersensitive to DNA damage
encountered during S phase. In corroboration of these results, in
colony survival assays, we also observed increased sensitivity of
SM-BLM cells to CPT compared to BLM+ cells (Figure S3). These
data indicated that SM-BLM cells are more sensitive than BLM+
cells to DNA damage generated during S phase, again consistent
with a defect in the repair of replication-associated DNA damage.
Replication Fork Damage Fails to Induce HR in
SUMO-Mutant BLM Cells
Replication-associatedDSBsarerepairedbyHR,whichgenerates
increased numbers of SCEs [1]. Because SM-BLM cells exhibited
Figure 2. SUMO-mutant BLM cells accumulate excess DSBs at damaged replication forks. (A) Pulsed-field gel showing the analysis of
untreated BLM+ and SM-BLM cells (NT) and cells treated with HU for 24 h (0 time) followed by release into normal medium for 12 and 24 h. DSBs were
visualized by DNA fragments that migrate into the gel, whereas intact DNA was retained in the well. (B) Quantification of DSBs after treatment with HU
and release into normal medium. The bars represent the numbers of DSBs relative to untreated BLM+ cells in two independent experiments with two
clones of each type, and the error bars represent the standard deviations of the combined data. (C) Quantification of accumulation of DSBs after
treatment with different concentrations of CPT for 3 h. Data points represent the numbers of DSBs relative to untreated BLM+ or SM-BLM cells from a
minimum of two experiments with two clones of each type. Error bars represent standard deviations of the combined data. (D) Quantification of HU-
inducedmicronuclei.Cellswereuntreatedortreatedwith0.5 mMHUfor24 h,followedbyincubationwith cytochalasin-Bfor28 h intheabsenceofHU.
Thenumbers ofmicronucleiwerecountedinbinucleatedcells.Aminimumof500binucleatedcellswere assessedundereach condition.Datapresented
are the average of three experiments in three BLM+ and three SM-BLM clones. The bars represent mean numbers of micronuclei, and error bars
represent standard deviations of the combined data. *p=0.6, NT SM-BLM versus NT BLM+;* * p,10
23, HU-treated SM-BLM versus HU-treated BLM+.
doi:10.1371/journal.pbio.1000252.g002
SUMO Modification Regulates BLM and RAD51 Function
PLoS Biology | www.plosbiology.org 4 December 2009 | Volume 7 | Issue 12 | e1000252excess HU-induced DSBs, we hypothesized that HR is impaired in
SM-BLM cells. Therefore, we tested whether replication stalling
inducedfewerSCEsinSM-BLMcomparedtoBLM+cells(Figure4).
Untreated BLM+ and SM-BLM cells showed similar numbers of
SCEs (17.4 vs. 16.7 SCEs/46 chromosomes, respectively). However,
whereas HU treatment induced a 2-fold increase in SCEs in BLM+
cells (from 17.4 to 29.6 SCEs/46 chromosomes; p,0.001), HU
treatment had almost no effect on the levels of SCEs in SM-BLM
cells (from 16.7 to 18.5 SCEs/46 chromosomes; p=0.32). The
numbers of HU-induced SCEs in BLM+ compared to SM-BLM
cells was significantly different (p,0.001). In contrast to SM-BLM
cells, HU induced a large increase in SCEs in BS cells (Figure S4A).
These data suggest that HR repair is not engaged normally at
damaged replication forks, leading to the excess DSBs that are
observed in HU-treated SM-BLM cells.
It is worth noting that in our earlier report on BLM
SUMOylation [34], we found that the mean number of SCEs in
untreated SM-BLM cells was greater than the mean number in
BLM+ cells. This difference was caused by the presence in the
SM-BLM cultures of 5% of cells with SCE levels equal to levels
typically observed in BS cells, whereas we had detected no cells of
this type in the BLM+ cultures. In the present study, we did not
detect cells with high SCEs in the SM-BLM cultures; consequently,
we suggest that these high-SCE cells were produced by extinction
of SM-BLM expression in a small fraction of SM-BLM cells.
Localization of RAD51 to Damaged Forks Is Defective in
SUMO-Mutant BLM Cells
RAD51 is a key enzyme in HR repair, and normally it interacts
with BLM at damaged replication forks [19,20]. Because SM-BLM
cells exhibited a defect in HR-mediated repair after replication
stalling, we examined whether RAD51 and BLM colocalize
normally at c-H2AX–marked damage in SM-BLM cells (Figure 5).
In untreated cells, SM-BLM cells contained more RAD51 foci than
BLM+ cells (26.9 vs. 18.1 foci/cell). Similarly, as previously noted
[34], untreated SM-BLM cells contained more BLM foci (19.0 vs.
11.0 foci/cell) (Figure 5B). However, after treatment with 0.5 mM
HU for 24 h, whereas BLM+ cells exhibited a large increase in
RAD51 foci from 18.1 to 51.7 foci/cell, SM-BLM cells exhibited
only a modest increase from 26.9 to 34 foci/cell (Figure 5B).
Consistent with these observations, whereas HU treatment induced
substantial increases in RAD51-c-H2AX and RAD51-BLM colo-
calization in BLM+ cells, HU treatment induced only a modest
increase in these colocalizations in SM-BLM cells (Figure 5C and
Figure S5). In HU-treatment conditions, whereas 66% of the
c-H2AXfocicontainedRAD51 inBLM+ cells(vs.58%inuntreated
cells),only25% of c-H2AX focicontainedRAD51 inSM-BLMcells
(vs. 43% in untreated cells—a decrease). As a positive control, we
found that RAD51 showed much higher levels of colocalization with
c-H2AX in HU-treated BS cells compared to BLM+ cells (Figure
S4B), as previously reported [19].
To distinguish whether the RAD51 localization defect was an
early or late effect of replication stalling, we treated BLM+ and
SM-BLM cells with 10 mM HU for 1 h and stained cells with
antibodies to RAD51 and PCNA (to identify cells in S phase).
Whereas BLM+ cells exhibited a 2.3-fold increase in RAD51 foci
from 14.4 to 33.6 foci/cell in PCNA-positive cells, SM-BLM
cells exhibited no increase in total RAD51 foci from 19.7 to 21.0
foci/cell (Figure 5D). Synchronization experiments with mimosine
followed by treatment with 10 mM HU for 1 h corroborated these
data (Figure S6). It is worth noting that both BLM+ and SM-BLM
proteins localized efficiently with PCNA foci in HU-treated cells,
indicating that SUMOylation is not required for normal trafficking
of BLM to stalled forks (Figure S7).
Altogether, these data demonstrated that there is a dramatic
defect in RAD51’s recruitment to and/or retention in repair foci
induced by replication stalling. The RAD51 localization defect
could explain both the impairment of HR after replication stalling
and the excess DSBs observed in SM-BLM cells.
RAD51 Binds SUMOylated BLM
To investigate the mechanism that might explain the RAD51
localization defect, we considered the possibility that RAD51
interacts with SUMO noncovalently, which would facilitate
Figure 3. SM-BLM cells are hypersensitive to DNA damage
encountered during S phase. Cells were untreated (NT) or treated
with 0.5 mM HU for 24 h and then untreated or treated with 50 mM
etoposide for 24 h. Cell viability was measured using the Guava
ViaCount reagent, and cell death was calculated as the percentage of
dead cells divided by the total number of cells. The bars represent the
mean percentage of dead cells in each condition in three BLM+ clones
and three SM-BLM clones from a minimum of three independent
experiments performed in triplicate. Error bars represent standard
deviations of the combined data. See text for p-values of relevant
comparisons.
doi:10.1371/journal.pbio.1000252.g003
Figure 4. Cells that express SUMO-mutant BLM do not exhibit
increased HU-induced SCEs. BrdU was incorporated for one cell-
division cycle prior to HU treatment. Cells were treated with 0.5 mM HU
for 24 h and then released into BrdU-containing medium for another
20 h. Metaphases were collected in colcemid. The bars represent the
mean numbers of SCEs in two BLM+ and two SM-BLM clones from a
minimum of three independent experiments. Error bars represent
standard deviations of the combined data. See text for p-values of
relevant comparisons.
doi:10.1371/journal.pbio.1000252.g004
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hypothesis, we assayed for possible noncovalent interactions
between RAD51 and SUMO and also for possible effects of
covalent SUMOylation of BLM on its interactions with RAD51
(Figure 6). In an in vitro binding assay, more RAD51 bound to
SUMO-coated beads than to controls beads (Figure 6A), showing
that RAD51 binds equally well to both SUMO-1 and SUMO-2.
To test whether SUMO modification of BLM affects its
interaction with RAD51, we incubated RAD51-coated beads with
either unmodified BLM or with a mixture of SUMO-2–modified
and unmodified BLM and analyzed bound proteins by Western
blot with anti-BLM antibodies. Consistent with previous find-
ings [20], unmodified BLM bound specifically to RAD51-
coated beads, confirming that BLM and RAD51 interact directly
(Figure 6B, left panel). SUMO-2–modified BLM also bound
specifically to RAD51-coated beads (Figure 6B, right panel). To
evaluate the effect of SUMO-2 modification on BLM’s interaction
with RAD51, the results of the binding assays were analyzed
quantitatively. This analysis revealed that, whereas the ratio of
SUMO-2–modified to unmodified BLM in input fractions and
Figure 5. RAD51 has a localization defect in HU-treated SM-BLM cells. (A) Immunofluorescence images of BLM+ and SM-BLM cells treated
with 0.5 mM HU for 24 h or not treated (NT) and stained for c-H2AX and RAD51. Bars indicate 10 mm. (B) Graphical representation of mean numbers
of RAD51 and BLM foci in HU-treated and untreated BLM+ and SM-BLM cells. *p=0.09, NT SM-BLM versus NT BLM+;* * p=0.02, HU-treated SM-BLM
versus HU-treated BLM+. #p=0.01, NT SM-BLM versus NT BLM+; ##p=0.01, HU-treated SM-BLM versus HU-treated BLM+. (C) Graphical
representation of mean numbers of colocalized RAD51-c-H2AX and colocalized BLM-c-H2AX foci in HU-treated and untreated BLM+ and SM-BLM
cells. *p,10
23, NT SM-BLM versus NT BLM+;* * p,10
23, HU-treated SM-BLM versus HU-treated BLM+; #p,10
23, NT SM-BLM versus NT BLM+;
##p=0.02, HU-treated SM-BLM versus HU-treated BLM+. Bars in (B) and (C) represent the average foci in three independent experiments of three
BLM+ and three SM-BLM clones. Error bars represent the standard deviations of the combined data. (D) Graphical representation of means numbers
of RAD51 foci in untreated cells or cells treated with 10 mM HU for 1 h. RAD51 foci were counted in cells that stained positively with PCNA
antibodies. Bars represent the average foci in two independent experiments of two BLM+ and two SM-BLM clones. Error bars represent the standard
deviations of the combined data.
doi:10.1371/journal.pbio.1000252.g005
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1.7:1, respectively, the ratio present in fractions retained on
RAD51-coated beads was approximately 5.1:1 (Figure 6C). These
binding ratios reveal that SUMO-2 modification of BLM has a
strong, positive effect on its binding to RAD51.
Altogether, these data demonstrated that RAD51 contains a
SUMO binding site(s) and that SUMOylation of BLM can affect
its interactions with RAD51. The data support the hypothesis that
SUMOylation of BLM facilitates repair of damaged replication
forks by HR by modulating RAD51’s recruitment and/or
retention at repair sites.
Discussion
The data presented here demonstrate the importance of BLM
SUMOylation in the repair of damaged replication forks. Failure
to SUMOylate BLM resulted in excess damage-induced repair
foci, DSBs, and hypersensitivity to DNA damage. Importantly, in
SM-BLM cells, replication stalling by HU did not stimulate HR as
measured by SCEs, suggesting a defect in RAD51 function.
Consistent with these data, RAD51 failed to accumulate at stalled
forks. SUMO-mutant BLM exerts a dominant effect, because
excess c-H2AX foci were induced by expression of SUMO-mutant
BLM in HeLa cells, which express endogenous normal BLM [34].
Moreover, we showed here that several SM-BLM phenotypes
differed from BS phenotypes, such as the presence of excess H2AX
phosphorylation in untreated cells, the RAD51 localization defect,
and the lack of HU-induced SCEs. We found that RAD51 is a
SUMO-binding protein, implicating BLM SUMOylation in
recruitment of RAD51 to repair sites through a mechanism
involving noncovalent SUMO interactions. Our findings demon-
strate that BLM SUMOylation regulates the recruitment and/or
retention of RAD51 to damaged replication forks, and it is
important in HR-mediated repair.
The steady-state levels of DSBs in cells are a function of the rate
at which DNA damage accumulates and the rate at which it is
repaired. We observed that SM-BLM cells exhibited greater
numbers of DSBs than BLM+ cells under a variety of conditions
(Figure 2). For example, SM-BLM cells exhibited more HU-
induced DSBs, which arise due to breakage of stalled forks, and
more CPT-induced DSBs, which arise due to replication runoff at
sites where topoisomerase-cleavage complexes are bound to the
DNA [38]. Formally, the presence of increased levels of DSBs in
SM-BLM cells could result from an increase in the rate at which
DNA damage accumulates (due to excess numbers of replication
forks, increased numbers of topoisomerase cleavage complexes, or
a failure to process aberrant replication intermediates) or from a
decrease in the rate of DNA repair (due to a failure to recruit
RAD51). We noted that the rate of DSB accumulation after
release from the HU block was the same in both SM-BLM and
BLM+ cells, indicating that the rate of breakage exceeds the rate of
repair under these conditions in both types of cells. Consistent with
these observations, the numbers of c-H2AX foci in both BLM+
and SM-BLM cells increase 6 h after release from the HU block
(unpublished data).
Recent work has shown that BLM is present on a class of
ultrafine anaphase bridges [39], and it acts to separate interlinked
DNA strands especially at loci with intrinsic replication difficulties
[40]. BS cells consequently have a defect in separation of sister
chromatids, resulting in more anaphase bridges; some fraction of
the increased DSBs that arise in BS cells no doubt traces to
breakage at sites of underreplicated DNA. BS cells exhibit an
inadequate response to replication stress [16,41–43], in which
additional forks are initiated apparently to compensate for forks
that have collapsed [44,45]. One possible explanation for the
excessive numbers of c-H2AX foci and DSBs in treated and
untreated SM-BLM cells is that these cells have increased
replication difficulties, as BS cells do, and they compensate by
activating additional replication forks, which are concomitantly
more likely to break after replication damage. According to this
view, BLM SUMOylation helps prevent the collapse of replication
forks in regions with hard-to-replicate DNA, perhaps by
stimulation of BLM’s activity in subverting aberrant recombina-
tion intermediates at stalled replication forks.
Alternatively, BLM SUMOylation could promote HR-mediated
repair of broken forks through the recruitment and/or retention of
Figure 6. RAD51 contains a SUMO binding site. (A) Biotinylated SUMO-1 and SUMO-2 were bound to streptavidin beads and incubated with
purified recombinant, human RAD51; the complexes were pulled down and analyzed by Western blot with anti-RAD51. As a control, unbiotinylated
SUMO-1 and SUMO-2 were incubated with beads and incubated with RAD51. (B) A purified, recombinant N-terminal fragment of BLM, consisting of
amino acids 1–431, was modified with SUMO-2 in vitro. Equal amounts of SUMOylated or unSUMOylated BLM were incubated with RAD51 bound to
streptavidin beads, and complexes were pulled down and analyzed by Western blot with anti-BLM. As a control, SUMOylated or unSUMOylated BLM
was incubated with unconjugated streptavidin beads. (C) Ratios of SUMO-2–modified BLM to unmodified BLM in input fraction and fractions bound
to control beads and beads containing RAD51. Experiment was performed three times. *p=0.03, RAD51-coated beads versus control beads.
doi:10.1371/journal.pbio.1000252.g006
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essential for HR-mediated DNA repair, and previous studies have
demonstrated that RAD51 and BLM interact specifically in DNA-
damaged cells [19,20]. On the basis of immunolocalization studies,
we found that the recruitmentand/orretentionofRAD51 atsitesof
stalled DNA replication forks is impaired in SM-BLM cells.
Whereas BLM+ cells exhibited a 4-fold increase in the number of
colocalized c-H2AX-RAD51 foci upon HU treatment, SM-BLM
cells exhibited a ,1.5-fold increase in these foci. On the basis of this
finding, and the finding that HR-mediated DNA repair is defective
in SM-BLM cells, we propose that BLM SUMOylation mediates
the recruitment and/or retention of RAD51 to sites of DNA
damage and thereby facilitates HR-mediated repair processes.
Previous cell and biochemical studies have led to the view that
BLM has both pro- and anti-recombinogenic functions. Most
notably, BLM is important in stabilizing damaged replication forks
[14–16] and repressing aberrant recombination events, as
evidenced by the dramatic increase in levels of SCEs and loss of
heterozygosity in BLM null cells [6,46]. In contrast, BLM is also
predicted to promote HR by facilitating exonucleolytic resection of
DSBs [23–26], by stimulating synthesis-dependent strand anneal-
ing [21,47], and by promoting noncrossover resolution of Holliday
junctions [12]. Both pro- and anti-recombinogenic functions have
likewise been proposed for Escherichia coli RecQ helicase [48]. Our
finding that cells expressing SUMO-mutant BLM have a defect in
the recruitment and/or retention of RAD51 to sites of DNA
damage, and that they are defective in HR-mediated repair,
supports a model in which SUMOylation of BLM acts as a switch
to regulate its effects on recombination (Figure 7). In the absence
of SUMOylation, we propose that BLM binds to stalled
replication forks and suppresses aberrant HR by inhibiting
excessive accumulation of RAD51 at repair sites. In the event
that a stalled replication fork progresses to a DSB, stimulation of
HR-mediated repair would be triggered by BLM SUMOylation
and, consequently, more efficient recruitment and/or retention of
RAD51 at the repair site.
SUMOylation of BLM could regulate the recruitment and/or
the retention of RAD51 at sites of DNA damage through several
different mechanisms. SUMOylation could dissociate BLM from
broken DNA ends, where it might otherwise inhibit RAD51
binding and function by displacing RAD51 from ssDNA or by
unwinding D-loops [21,22]. SUMOylation could limit the binding
of BLM to sites of DNA damage by altering its affinity to ssDNA
or possibly by triggering its ubiquitin-dependent degradation.
SUMO-mediated degradation has been described for PML and
other proteins [49–51]. In the model that we currently favor, BLM
SUMOylation could function to promote RAD51 localization at
repair sites by stabilizing its interactions with BLM through a
mechanism involving noncovalent SUMO binding. Consistent
with this model, we found that RAD51 is a SUMO-binding
protein and that it interacts more efficiently with SUMOylated
BLM compared to unmodified BLM. RAD51 is recruited to
damaged replication forks in BS cells [19,20] and to a limited
number of sites of DNA damage in SM-BLM–expressing cells.
Thus, multiple factors appear to control RAD51 recruitment to
sites of DNA damage. Nonetheless, our findings support the
hypothesis that in BLM-expressing cells, BLM SUMOylation
promotes RAD51 recruitment and/or retention at sites of DNA
damage and thereby facilitates HR-mediated DNA repair.
SUMOylation of BLM is likely to have multiple roles. In
addition to regulating its activity at sites of DNA damage as
revealed in the current study, BLM SUMOylation may also be
important in mediating the localization of BLM to PML-NBs in
undamaged cells. SUMO modification can function to retain
proteins in the PML-NBs [35], and fluorescence recovery after
photobleaching studies have shown that BLM rapidly associates
and dissociates from the PML-NBs [52]. This on–off process may
be mediated primarily through BLM’s SUMO interaction motif,
which is required for BLM localization to the PML-NBs and for
BLM SUMOylation [53,54]. The presence of a SUMO binding
site(s) in RAD51 suggests that its association with the PML-NBs
may also be regulated through the SUMO pathway.
Our results have broad implications for understanding not only
how the integrity of replication forks are maintained under stress
but also how SUMO modification regulates its substrates, because
many proteins in the DNA repair and signaling pathways are
SUMO substrates. Although the role of SUMO in HR function is
not yet understood, it is clear that SUMOylation plays multiple
roles in regulating the HR pathway through modifications of
various HR factors, including Sgs1 [32], Rad52 [55–57], PCNA
[58], and other recombination-associated factors. sgs1 mutants and
mutants of the SUMO-specific E3 ligase gene mms21 accumulate
aberrant cruciform structures at damaged replication forks
[32,33]. This genetic evidence suggests that SUMOylation is
important in the regulation of HR, but there has been no direct
evidence that SUMOylation occurs at the repair site. Because
SUMO-mutant BLM accumulates at HU-induced replication fork
damage, the present results indicate that BLM SUMOylation
occurs at the sites of damaged replication forks, where it affects
stabilization of stalled forks, trafficking of RAD51 to repair sites,
and HR repair of damaged forks. Further experiments are now
needed to characterize the spatial and temporal regulation of
SUMOylation of the different repair factors in HR. In particular,
we need to determine what signals activate BLM SUMOylation
and how BLM SUMOylation is regulated at damaged forks.
Materials and Methods
Antibodies
For BLM Western analysis, rabbit polyclonal anti-BLM
antibodies raised against the first 431 amino acids of human
BLM [59] or commercially available antibodies (A300-110A,
Bethyl Laboratories) were used. Anti-SUMO antibodies were used
Figure 7. BLM SUMOylation regulates BLM and RAD51 function
in HR-mediated repair of damaged forks. The model depicts a
replication fork that has either stalled or broken. At stalled forks,
unSUMOylated BLM inhibits access of RAD51 to the stalled fork. If the
fork progresses to a DSB, BLM SUMOylation promotes the recruitment
and/or retention of RAD51 to the broken end through noncovalent
interactions between SUMOylated BLM and the SUMO binding site on
RAD51. S, SUMO.
doi:10.1371/journal.pbio.1000252.g007
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mouse monoclonal anti–c-H2AX antibody (Upstate), rabbit
polyclonal anti-RAD51 antibodies PC130 (Calbiochem), mouse
monoclonal anti-PCNA antibody sc-56 (Santa Cruz Biotechnol-
ogy), Cy-5–labeled donkey anti-rabbit antibodies (Jackson Labs),
Alexa Fluor 594–labeled goat anti-mouse, Alexa Fluor 594–
labeled goat anti-rabbit, and Alexa Fluor 647–labeled goat anti-
mouse antibodies (Invitrogen). Rat monoclonal anti-Hsc70
antibodies (Assay Design) were used as a loading control in
Western analyses.
BLM Expression Constructs and Stable Cell Lines
The full-length BLM cDNA was cloned into the EGFP-C1
vector (Clontech), which produced a GFP-BLM fusion protein
with GFP at the N-terminus of BLM, as described previously [53].
The GFP-BLM construct was used as a template for the
construction of BLMs that contain SUMO acceptor-site muta-
tions, by substituting arginine for lysine at amino acid residues 317
and 331 using standard polymerase chain reaction–based methods
[34]. The construct used in the experiments reported here
contained mutations at both 317 and 331. We stably expressed
the normal BLM and SUMO-mutant BLM constructs in the
SV40-transformed fibroblast cell line GM08505 (BS cells) and
isolated multiple clones expressing each construct, as described
previously [34,60]. To measure the levels of GFP-BLM expression,
we prepared cell lysates in Laemli sample buffer, fractionated
proteins by sodium dodecyl sulphate-polyacrylamide gel electro-
phoresis, and transferred the proteins to nitrocellulose membranes
(Bio-Rad). The membranes were then processed for Western blot
analysis and probed with anti-BLM antibodies as described earlier
[53]. Varying levels of BLM expression were detected in BLM+
and SM-BLM clones. We chose BLM+ and SM-BLM clones that
had comparable levels of transgene expression.
To measure DNA content and percentage of cells in each phase
of the cell cycle, cells were harvested by trypsinization and fixed in
70% ethanol for .3ha t220uC. After fixation, cells were pelleted
and resuspended in a solution of 16 phosphate buffered saline
(PBS; Gibco) containing propidium iodide (10 mg/ml) and RNase
A (0.1 mg/ml). The fluorescence intensities of the propidium
iodide–stained cells were measured using a FACScalibur (Becton-
Dickinson), and data were analyzed with CellQuest (Becton-
Dickinson) and WinMDI (Joe Trotter; http://facs.scripps.edu)
software. To examine the percentage of cells in S phase, cells were
treated with HU, released, and then analyzed at times after release
using the BrdU Flow Kit (BD Biosciences) according to the
manufacturer’s instructions. BLM+ and SM-BLM cell clones in
the logarithmic phase of cell proliferation had comparable
proliferation rates, with cell-doubling times equal to ,30 h for
each clone examined.
Immunofluorescence and Image Analysis
BLM+ and SM-BLM cells were seeded on coverslips and then
treated with 10 mM or 0.5 mM HU in culture medium for 1 or
24 h, respectively. To achieve cell synchronization through an
independent mechanism, BLM+ and SM-BLM cells were seeded
onto coverslips and treated with 0.5 mM mimosine for 24 h. The
cells were released into normal medium for 5 h to allow entry into
S phase, then treated or not with 10 mM HU for 1 h. For indirect
immunofluorescence, cells were washed and fixed at the end of
HU treatment. They were then stained with anti-RAD51 and with
anti–c-H2AX or anti-PCNA antibodies, and counterstained with
secondary antibodies labeled with Alexa Fluor (Invitrogen).
Fixation and staining was performed as described previously
[34]. Coverslips were mounted with Prolong Gold antifade reagent
containing 49,6-diamidino-2-phenylindole (DAPI) (Invitrogen).
Images were captured on a spinning disk confocal microscope
(Carl Zeiss, LSM-510), and data were collected using Slidebook
4.1 software. Z-stacks were captured using a 1006oil immersion
objective, and the optical slice thickness was 0.2 mm.
A focus was defined as a defined area of the nucleus greater than
the minimum area of optical resolution (.0.125 mm
2) in at least
one Z-stack in which the fluorescence intensity was greater than
the background fluorescence intensity of the nucleoplasm.
Colocalization was defined as an area of overlap between two
foci of different fluorophores. The maximum number of foci that
could be counted in these cells was 150. For purposes of
quantification of c-H2AX foci in the c-H2AX-bright cells, the
c-H2AX-bright cells were assigned 151 foci, which was one focus
more than the maximum countable number. A typical immuno-
fluorescence experiment consisted of assessment of 30–50 cells per
condition. The data presented are from two to three independent
experiments performed on two or three clones of each type.
Immunofluorescence images for figures were created using Image
J and Metamorph software (Molecular Devices).
Flow Cytometry Analysis of c-H2AX Levels
Cells were untreated or treated with 0.5 mM HU for 24 h.
Immediately after treatment, cells were harvested, washed twice
with PBS, resuspended in fixation solution (2.3% paraformalde-
hyde,0.6% methanol)ata densityofapproximately 1610
6 cells/ml,
and incubated on ice for 20 min. Following the fixation process,
cells were washed twice with PBS to remove the fixative and were
resuspended in permeabilization solution (0.25% saponin, 10 mM
HEPES [pH 7.4], 140 mM NaCl, 2.5 mM CaCl2) at a concentra-
tion of approximately 5610
6/ml. Cells were incubated overnight at
4uC in Alexa Fluor 647–conjugated anti-H2A.X (BioLegend). After
incubation, the cells were washed twice with 0.1% saponin and 5%
fetal bovine serum in PBS and were resuspended in 5% fetal bovine
serum in PBS for analysis. Cells were analyzed on a FACScaliber as
described above. Data were collected from a minimum of two
experiments on five BLM+ clones and six SM-BLM clones. Median
fluorescence intensity data was log normalized, and the differences
in median intensity were calculated. Log-normalized median
intensity differences were tested by Student’s t-test.
Measurement of DSBs by PFGE
Cells were untreated or treated with 0.5 mM HU for 24 h and
subsequently released into fresh medium for an additional 0, 12, or
24 h, or they were treated with different concentrations of CPT for
3 h. For each damage condition, 4610
5 cells were formed into
individual 1% agarose plugs (Cleancut agarose, Bio-Rad). The
plugs were then incubated in 100 mM EDTA (pH 8.0), 0.2%
sodium deoxycholate, 1% sodium lauryl sarcosine, and 1 mg/ml
proteinase K at 50uC for 24 h. The plugs were washed four times
in 10 mM Tris-HCl (pH 8.0) and 1 mM EDTA for 30 min at
room temperature with gentle agitation. Plugs were loaded onto a
0.8% agarose gel (Pulsed Field Certified Agarose, Bio-Rad), and
PFGE was preformed on a CHEF DR III (96u, 100u, 106u angle
ramp, 1,200–1,800 s switch time, 2 V/cm; Bio-Rad) for 72 h. The
gel was stained with SYBR Gold, visualized under UV light, and
analyzed using Quantity One and ImageJ software after contrast
adjustment. Each lane on the gel was divided into seven areas, and
the intensity in each area was analyzed and weighed according
to fragment size. The amount of breakage in each lane was further
normalized against total DNA content. Values are given relative
to the level of DNA breakage in the untreated control. At least
two independent experiments were performed on two clones of
each type.
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Exchanges and Micronuclei Formation
For SCE analyses, cells were cultured with 10 mM BrdU
(Sigma-Aldrich). After 60 h, the cells were incubated with
0.02 mg/ml colcemid (Invitrogen) for up to 2 h, harvested and
processed as described earlier [60]. The slides were examined
under the microscope at 1006, and SCEs were counted from
metaphases with an acceptable quality of sister-chromatid
discrimination. For measurements of HU-induced SCEs, cells
were cultured in 10 mM BrdU for 30 h, washed one time with 16
PBS, and treated with 0.5 mM HU for 24 h. Next, the cells were
released into medium containing 10 mM BrdU for an additional
20 h. Metaphases were collected in colcemid and processed as
described above. Two independent experiments were performed
on two clones of each type.
To quantify the cytogenetic effects of replication-associated
DSBs, cells were treated with HU, and micronuclei formation was
assessed using the cytokinesis-block micronucleus assay [61,62].
Cells were plated on chamber slides (Lab-Tek) for approximately
48 h. Next, cells were treated with 0.5 mM HU for 24 h, after
which the cells were washed thoroughly with PBS and then
incubated in culture medium containing 8.7 mM cytochalasin-B
(Sigma-Aldrich). After 28 h of cytochalasin-B treatment, cells were
fixed on the slides with a 9:1 methanol:acetic acid solution and
then stained with Diff-Quik (Baxter) according to the manufac-
turer’s instructions. Using a blinded analysis, we examined cells
under a light microscope at 1006. A minimum of 500 binucleated
cells were assessed under each condition and categorized as
follows: cells with no micronucleus, one micronucleus, more than
one micronucleus, and nucleoplasmic bridges. Three independent
experiments were performed on three clones of each type.
Cell Death Measurement
To measure cell viability under different DNA damage
conditions, 2610
5 cells were seeded onto six-well dishes. Cells
were treated or not treated with 0.5 mM HU for 24 h and then
treated or not treated with 50 mM of etoposide for an additional
24 h. At the end of the second treatment, the cell-growth medium
was retained, and the floating cells were combined with adherent
cells harvested by trypsinization. We added the ViaCount reagent
(Guava Technologies) according to the manufacturer’s instruc-
tions. Live and dead cells were counted with the Guava Cell
Analyzer. A minimum of three independent experiments with
three replicates for each condition were performed on three clones
of each type.
Measurement of SUMO-Dependent Binding
Human RAD51 protein was purified as described previously
[63]. The purified hRAD51 was either cleaved from the
streptavidin-conjugated agarose beads (Ultralink, Pierce) using
tobacco etch virus protease or left on the beads and directly used
for the binding reactions. SUMO was biotinylated by Sulfo-NHS-
Biotin (EZ-link, Pierce) according to the manufacturer’s instruc-
tions. Equal amounts of unbiotinylated and biotinylated SUMO-1
and SUMO-2 proteins were incubated with RAD51 in binding
buffer (PBS with 0.1% Triton X-100) for 2 h at 4uC. Streptavidin
beads were then added to each reaction and incubated for another
1 h at 4uC. After five washes with binding buffer, proteins were
eluted by SDS-PAGE buffer and analyzed by Western blotting
with RAD51 antibodies.
BLM N-terminal fragment (1–431) was modified by SUMO-2
in vitro as described [54]. The SUMO-modified BLM was then
aliquoted equally into two tubes with either RAD51-coated
streptavidin beads or biotin-coated beads, and rotated in the
binding buffer in the presence of 2% BSA at 4uC for 2 h.
Unmodified BLM was used as a control. The eluted protein was
analyzed by SDS-PAGE and Western blotting with anti-BLM
antibodies. Fujifilm Multi Gauge image analysis software (Fujifilm
Corp.) was used to determine relative Western blot band
intensities and ratios of SUMO-2–modified to unmodified BLM.
Statistical Analysis
Because observations within each clone may be correlated, we
used mixed effects linear models to test the data for statistical
significance. In the mixed effects models, each clone was treated as
a random effect, and the experimental variables were treated as
fixed effects. Because the foci and micronuclei data were not
normally distributed, we first applied a square root transformation
to stabilize the variance and normalize the data (results in the
figures were still presented in the original scale). For testing
changes in the number of foci per cell and the number of
colocalized foci per cell, cell type (BLM or SM-BLM), treatment
(with and without HU), and interaction terms for cell type by
treatment were treated as fixed effects. Similarly, for testing
changes in the number of micronuclei per cell and the number of
SCEs per 46 chromosomes, cell type, treatment with HU, and
their interaction were treated as fixed effects. Finally, for testing
changes in percentage of cell death, cell type, treatment with HU,
treatment with etoposide, and their interaction terms were
included as fixed effects. If the random effects (i.e., the clonal
variation) were found to be nonsignificant based on likelihood
ratio test, the mixed effect models reduced to traditional analysis
of variance.
Supporting Information
Figure S1 BLM+ and SM-BLM cells have similar cell-cycle
profiles. Representative cell-cycle profiles of cells expressing
BLM or SUMO-mutant BLM after HU treatment as deter-
mined by BrdU incorporation and flow cytometry analysis. Cells
were untreated (NT) or treated with 0.5 mM HU for 24 h. Cells
were then analyzed at 0 h, 1 h, 3 h, and 6 h after release from the
HU block. Greater than 80% of the cells were in S phase after
release from the HU block.
Found at: doi:10.1371/journal.pbio.1000252.s001 (0.42 MB PDF)
Figure S2 BS cells accumulate excess DSBs at damaged
replication forks. Quantification of DSBs in untreated BS cells
(GM08505) (NT) or cells treated with 0.5 mM HU for 24 h,
followed by release into normal medium for 0, 12, and 24 h. Bars
represent the numbers of DSBs relative to untreated BS cells in
three independent experiments. Error bars represent standard
deviation of the data.
Found at: doi:10.1371/journal.pbio.1000252.s002 (0.01 MB PDF)
Figure S3 SM-BLM cells are hypersensitive to campto-
thecin (CPT) compared to BLM+ cells, as determined by
colony survival assays. A total of 1,000–25,000 cells were
seeded onto six-well plates overnight, untreated or treated with
different concentrations of CPT for 3 h. After treatment, cells were
allowed to form colonies in normal medium. Percentage colony
survival was calculated as [number of colonies]treated/[number of
colonies]untreated6100. Data represent a single experiment per-
formed on five BLM clones and four SM-BLM clones. GM08505 is
the parental BS SV40-transformed human fibroblast cell line and
GM00637 is a normal SV40-transformed human fibroblast control;
the experiment was performed two times for these cell lines.
Found at: doi:10.1371/journal.pbio.1000252.s003 (1.88 MB PDF)
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phenotypes. (A) HU induces increased levels of SCEs in BS cells.
BS cells (GM08505) were incubated with 10 mM BrdU for 30 h,
treated or not with 0.5 mM HU for 24 h, and then returned to
BrdU-containing medium for an additional 20 h. Metaphases
were collected in colcemid. Two photomicrographs are shown of
metaphases in which exchanges between sister chromatids were
visualized. Average numbers of SCEs/46 chromosomes for
untreated and HU-treated BS cells is shown beneath the
photomicrographs (number of metaphases counted). (B) HU-
treated BS cells (GM08505) exhibit excess colocalization of
RAD51 and c-H2AX, demonstrating that RAD51 is effectively
recruited to damaged replication forks in the absence of BLM.
Bars indicate 10 mm.
Found at: doi:10.1371/journal.pbio.1000252.s004 (5.80 MB PDF)
Figure S5 Graphical representation of mean numbers
of colocalized RAD51 and BLM foci in untreated (NT)
and HU-treated (HU) BLM+ and SM-BLM cells.
Found at: doi:10.1371/journal.pbio.1000252.s005 (0.01 MB PDF)
Figure S6 Impaired localization of RAD51 to damaged
forks in SUMO-mutant BLM cells after a short treat-
ment with HU. BLM+ and SM-BLM cells were untreated (NT)
or synchronized with 0.5 mM mimosine for 24 h, which stalls cells
in late G1 phase, released into normal medium for 5 h to allow the
cells to enter S phase, then treated (MIM+HU) or not (MIM rel)
with 10 mM HU for 1 h and evaluated for RAD51 localization
with BLM and c-H2AX. BrdU flow cytometry, as performed in
Figure S1, confirmed that .80% of the cells had entered S phase
by 5 h after release. Data presented are the average of two
experiments in each of two BLM+ and two SM-BLM clones. Bars
represent the mean numbers of foci or colocalized foci per nucleus,
and the error bars represent the standard deviations of the
combined data. After 1 h of treatment with 10 mM HU, RAD51
foci increased in BLM+ cells but were effectively unchanged in
SM-BLM cells. These effects on RAD51 localization are observed
despite the fact that mimosine treatment induces many c-H2AX
foci, which has been previously reported [64].
Found at: doi:10.1371/journal.pbio.1000252.s006 (0.01 MB PDF)
Figure S7 BLM and SM-BLM localize to stalled replica-
tion forks with similar efficiency. (A) Immunofluorescence
images of representative S-phase BLM+ and SM-BLM cells
treated with 0.5 mM HU for 24 h. Cells were stained with
antibodies to PCNA. Images show GFP-BLM fluorescence, PCNA
staining, and merged BLM-PCNA immunofluorescence. (B)
Graphical representation of the average numbers of BLM foci,
PCNA foci, and colocalized BLM-PCNA foci in HU-treated
BLM+ and SM-BLM cells. The numbers of BLM and PCNA foci
were counted in cells that stained positively for PCNA, as these
represented cells in S phase. Data presented are the average of two
experiments in each of two BLM+ and two SM-BLM clones. Bars
represent the mean numbers of foci or colocalized foci per nucleus,
and the error bars represent the standard deviations of the
combined data. The levels of BLM foci and PCNA foci were
higher in SM-BLM than in BLM+ cells; however, the percentages
of colocalized BLM-PCNA foci were similar in BLM+ and SM-
BLM cells, indicating that SUMO-mutant BLM localizes normally
to sites of replication damage.
Found at: doi:10.1371/journal.pbio.1000252.s007 (0.99 MB PDF)
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